Media stories about Penumbra (NYSE:PEN) have trended somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Penumbra earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.9700087008183 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
PEN has been the topic of a number of analyst reports. BidaskClub upgraded Penumbra from a “hold” rating to a “buy” rating in a report on Thursday, June 22nd. Zacks Investment Research downgraded Penumbra from a “hold” rating to a “sell” rating in a report on Thursday, May 11th. BMO Capital Markets restated a “buy” rating and set a $96.00 target price on shares of Penumbra in a research note on Friday, June 16th. Finally, Canaccord Genuity restated a “buy” rating and set a $94.00 target price on shares of Penumbra in a research note on Tuesday, June 13th.
Shares of Penumbra (NYSE PEN) opened at 83.15 on Friday. The firm’s 50-day moving average price is $85.06 and its 200-day moving average price is $82.68. The firm has a market cap of $2.81 billion, a PE ratio of 561.82 and a beta of 0.10. Penumbra has a 12 month low of $56.05 and a 12 month high of $91.00.
Penumbra (NYSE:PEN) last released its quarterly earnings results on Tuesday, August 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.05). Penumbra had a negative return on equity of 2.58% and a negative net margin of 2.78%. The firm had revenue of $80.60 million for the quarter, compared to analyst estimates of $77.16 million. During the same quarter last year, the company posted $0.01 earnings per share. The business’s revenue was up 23.8% on a year-over-year basis. Analysts expect that Penumbra will post ($0.21) earnings per share for the current year.
In related news, EVP Robert D. Evans sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, August 9th. The shares were sold at an average price of $85.15, for a total value of $851,500.00. Following the completion of the sale, the executive vice president now owns 11,704 shares in the company, valued at $996,595.60. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Thomas Wilder sold 345 shares of the firm’s stock in a transaction dated Tuesday, July 18th. The shares were sold at an average price of $86.10, for a total transaction of $29,704.50. The disclosure for this sale can be found here. In the last three months, insiders have sold 42,345 shares of company stock worth $3,422,645. Corporate insiders own 22.00% of the company’s stock.
About Penumbra
Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.
Receive News & Ratings for Penumbra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
